Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Non-Current Assets (2021 - 2025)

ARS Pharmaceuticals' Other Non-Current Assets history spans 5 years, with the latest figure at $3.1 million for Q2 2025.

  • For Q2 2025, Other Non-Current Assets changed N/A year-over-year to $3.1 million; the TTM value through Jun 2025 reached $3.1 million, changed N/A, while the annual FY2024 figure was $3.1 million, 14728.57% up from the prior year.
  • Other Non-Current Assets for Q2 2025 was $3.1 million at ARS Pharmaceuticals, down from $3.1 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $3.2 million in Q3 2023 and bottomed at $21000.0 in Q4 2023.
  • The 5-year median for Other Non-Current Assets is $350000.0 (2021), against an average of $1.5 million.
  • The largest annual shift saw Other Non-Current Assets tumbled 99.29% in 2023 before it skyrocketed 14728.57% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $250000.0 in 2021, then skyrocketed by 1084.4% to $3.0 million in 2022, then crashed by 99.29% to $21000.0 in 2023, then surged by 14728.57% to $3.1 million in 2024, then decreased by 2.02% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Other Non-Current Assets are $3.1 million (Q2 2025), $3.1 million (Q4 2024), and $21000.0 (Q4 2023).